Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Soccer
Donald Trump
Social Media
European Union
Taxes
Property
World Cup
Natural Disasters
Housing
Republican Party
Cryptocurrency
ophthalmologytimes.com image

News from ophthalmologytimes.com

We’ve assigned a media bias rating of unknown to ophthalmologytimes.com. You can read more about our methodology here.

Information about ophthalmologytimes.com

Where is ophthalmologytimes.com located?ophthalmologytimes.com's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ophthalmologytimes.com News

ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
Knoxville, Tennessee · Knoxville

ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease

56% Center coverage: 37 sources
Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye disease.See the Story
CIT Weighs Pausing Still-Pending IEEPA Suits to Await Appellate Decisions
Donald Trump · United States

CIT Weighs Pausing Still-Pending IEEPA Suits to Await Appellate Decisions

100% Center coverage: 3 sources
Plaintiffs in two Court of International Trade tariff suits are clashing with the Justice Department over whether their cases should continue after CIT struck down President Trump’s International Economic Emergency Powers Act duties, with each side arguing that its approach will simplify the complex litigation now playing out in multiple courts. Following CIT’s May 28 ruling that the tariffs exceeded Trump’s statutory authority, DOJ has asked th…See the Story
Prevent Blindness Declares June as Cataract Month

Prevent Blindness Declares June as Cataract Month

Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and surgery options.See the Story

FDA accepts NDA for Tenpoint Therapeutic’s brimochol PF for presbyopia

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026.United States · United StatesSee the Story

Study highlights retinal vulnerability in patients with bipolar and depressive disorders

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings suggest that neurologic diseases impact ocular health.Alzheimer's DiseaseSee the Story

The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term patient care.Read Article

ASCRS 2025: Steven R. Sarkisian Jr., MD, ABO, envisions a future without glaucoma drops

At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.Read Article

Telomir announces positive preclinical data for its novel oral AMD therapeutic

Telomir-1 shows promising results in restoring vision and retinal structure in age-related macular degeneration, marking a significant advancement in treatment.AMDRead Article

Q&A: Rachel Downes, MD, provides highlights from the GATHER1 and GATHER2 clinical trials for GA

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.Maryland · MarylandRead Article

Ocular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMD

The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.AMDSee the Story

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine ...

100% Center coverage: 1 sources
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placeboPhase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a…See the Story

Breaking News Topics Related to ophthalmologytimes.com

AMD

AMD

Salt Lake County

Salt Lake County

Salt Lake City

Salt Lake City

Utah

Utah

Maryland

Maryland

United States

United States

News
For You
SearchBlindspotLocal